arrow
R

Richard F. Schlenk

core center
H指数:89
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial

作者更正: 新诊断的星形细胞瘤中的IDH1-mutant疫苗: 多中心,单臂,开放标签,人类第一阶段NOA16试验的最终分析

2026-08-030
OAAI
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial

IDH1突变疫苗在新诊断星形细胞瘤中的应用:多中心、单臂、开放标签、首次人体1期NOA16试验的最终分析

2026-07-010
OAAI
Quizartinib in newly diagnosed patients with FLT3-ITD–positive AML who received maintenance therapy in QuANTUM-First

Quizartinib在QuANTUM-First研究中,接受维持治疗的初诊FLT3-ITD阳性AML患者中的应用

2026-04-090
OAAI
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor

多层分子分析为硬化性小圆细胞肿瘤的诊断和靶向治疗提供信息

2026-04-090
OA
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

在转移性乳腺癌中实施精准肿瘤学:全面基因组分析的临床影响——CATCH研究经验

2025-10-310
OAAI
FLT3-ITD measurable residual disease from the QuANTUM-First trial

FLT3-ITD可测量残留病灶来自QuANTUM-First试验

2025-10-080
OAAI
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/ 5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial

PAMSARC(在表达SSTR2/3/5的滑膜肉瘤和弥漫性小圆细胞瘤中使用帕西瑞肽作为每月深部肌肉注射的维持治疗)多中心II期试验的原理与设计

2025-09-010
OAAI
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
2024-12-030
OAAI
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

10年随访研究:CALGB 10603/Ratify试验中,年龄18-60岁新诊断FLT3突变急性髓系白血病患者的米哚妥林与安慰剂联合强化化疗的比较

BLOOD
IF23.1
2024-11-050
PRE
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/hypomethylating agents
2024-10-030
OAAI
Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial

Inavolisib在具有激活性PIK3CA突变的癌症中的研究:CRAFT试验的结果

2024-09-010
PRE
Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study

帕希瑞otide作为SSTR2/3/5表达型滑膜肉瘤和硬化性小圆细胞瘤的维持治疗:PAMSARC研究

2024-09-010
PRE
COGNITION/-GUIDE - Implementation of Precision Oncology in Early High-Risk Breast Cancer
2024-05-020
PRE
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia
2024-02-220
OAAI
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

首次人体临床试验的方案,以评估双特异性CD276xCD3抗体CC-3在结直肠癌患者中的安全性,耐受性和初步疗效 (CoRe_CC-3)

2024-02-120
OAAI
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
2023-12-074
OAAI